03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
01:32 , Mar 25, 2015 |  BC Extra  |  Politics & Policy

CMS to emphasize clinical utility of prognostic cancer tests

At Tuesday's meeting of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) to discuss prognostic tests for cancer, CMS's James Rollins said the agency will rely more heavily on clinical utility, in addition to...
02:28 , Jan 27, 2015 |  BC Extra  |  Politics & Policy

CMS to discuss prognostic tests for cancer

CMS's Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) will meet on March 24 to discuss molecular pathology tests for the prognosis of colorectal, breast and non-small cell lung cancer (NSCLC). The committee will review...
07:00 , Mar 25, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Polymerase (DNA directed)-g (POLG); POLB In vitro studies suggest that inhibiting DNA polymerases POLG and POLB could help treat cancers deficient in either of...
07:00 , Aug 27, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact nformation Cancer Cancer Checkpoint with forkhead and ring finger domains (CHFR); DNA mismatch repair protein Mlh1 (MLH1) Studies in patient tissue samples and in mice suggest that...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

Biomarker Panels diagnostic data

Data from 115 evaluable patients with triple negative breast cancers enrolled in a U.S. trial showed that a panel of 4 DNA repair proteins (XPF, FANCD2 , MLH1 and MK2 ) met the primary endpoint...
07:00 , Oct 2, 2000 |  BC Week In Review  |  Company News

Myriad Genetics sales and marketing update

MYGN launched its Colaris test that detects mutations in MLH1 and MSH2 genes associated with hereditary colorectal and uterine cancer. Myriad Genetics Inc. (MYGN), Salt Lake City, Utah   Business: Diagnostics/Imaging  ...